Cancer Immunotherapy via Targeting Cancer Stem Cells Using Vaccine Nanodiscs
Alireza Hassani Najafabadi, Jing Zhang, Marisa Aikins, Zeynab Izadi Najaf Abadi, Fei Liao, You Qin, Emeka B. Okeke, Lindsay Scheetz, Jutaek Nam, Yao Xu, David Adams, Patrick A. Lester, Taryn Hetrick, Anna Schwendeman, Max S. Wicha, Alfred E. Chang, Qiao Li, James J. Moon
Abstract
Cancer stem cells (CSCs) proliferate extensively and drive tumor metastasis and recurrence. CSCs have been identified in over 20 cancer types to date, but it remains unknown how to target and eliminate CSCs in vivo. Aldehyde dehydrogenase (ALDH) is a marker that has been used extensively for isolating CSCs. Here we present a novel approach to target and reduce the frequency of ALDHhigh CSCs by vaccination against ALDH. We have identified ALDH1-A1 and ALDH1-A3 epitopes from CSCs and developed synthetic high-density lipoprotein nanodiscs for vaccination against ALDHhigh CSCs. Nanodiscs increased antigen trafficking to lymph nodes and generated robust ALDH-specific T cell responses. Nanodisc vaccination against ALDHhigh CSCs combined with anti-PD-L1 therapy exerted potent antitumor efficacy and prolonged animal survival in multiple murine models. Overall, this is the first demonstration of a simple nanovaccine strategy against CSCs and may lead to new avenues for cancer immunotherapy against CSCs.